{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:17:17Z","timestamp":1793042237975,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.seminoncol.2026.152466","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:33:34Z","timestamp":1768548814000},"page":"152466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in the management of metastatic lobular breast cancer: Current evidence and emerging treatments"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-6679","authenticated-orcid":false,"given":"Ana Isabel","family":"Mart\u00edn-Quesada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-9652","authenticated-orcid":false,"given":"Carla","family":"Mart\u00edn-Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2026.152466_bib0001","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jama.289.11.1421","article-title":"Trends in incidence rates of invasive lobular and ductal breast carcinoma","volume":"289","author":"Li","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152466_bib0002","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-023-06882-7","article-title":"Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL","volume":"198","author":"Thill","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152466_bib0003","article-title":"Invasive lobular carcinoma of the breast: morphology, biomarkers and \u2019omics","volume":"17","author":"McCart Reed","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152466_bib0004","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1002\/onco.13734","article-title":"Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer","volume":"26","author":"Pramod","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152466_bib0005","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast Cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152466_bib0006","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-014-2861-6","article-title":"Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma","volume":"144","author":"Loibl","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.seminoncol.2026.152466_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40487-019-00105-0","article-title":"Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy","volume":"8","author":"Luveta","year":"2020","journal-title":"Oncol Ther"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152466_bib0008","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1245\/s10434-011-1907-9","article-title":"Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? Analysis of an institutional database over a 10-year period","volume":"19","author":"Fortunato","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152466_bib0009","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000521097","article-title":"Invasive lobular carcinoma has worse outcome compared with invasive ductal carcinoma in stage IV breast cancer with bone-only metastasis","volume":"17","author":"Luo","year":"2022","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.seminoncol.2026.152466_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2021.12.031","article-title":"Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study","volume":"164","author":"Dalenc","year":"2022","journal-title":"Eur J Cancer (1990)"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152466_bib0011","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.3390\/cancers15225491","article-title":"Lobular carcinoma of the breast: a comprehensive review with translational insights","volume":"15","author":"Batra","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152466_bib0012","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S1470-2045(21)00472-1","article-title":"Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4\/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis","volume":"22","author":"Gao","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2026.152466_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103257","article-title":"236P Survival outcomes of patients (pts) with metastatic lobular breast cancer (mLBC) receiving cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i) and endocrine therapy (ET): a retrospective analysis","volume":"9","author":"Castellano","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.seminoncol.2026.152466_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.591399","article-title":"Lobular breast cancer: a review","volume":"10","author":"Wilson","year":"2021","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152466_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41698-024-00508-x","article-title":"Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations","volume":"8","author":"Dopeso","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152466_bib0016","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2833","article-title":"Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer","volume":"13","author":"Sanchez","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"20","key":"10.1016\/j.seminoncol.2026.152466_bib0017","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152466_bib0018","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.seminoncol.2026.152466_bib0019","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152466_bib0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"10.1016\/j.seminoncol.2026.152466_bib0021","doi-asserted-by":"crossref","first-page":"LBA1001","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1001","article-title":"Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician\u2019s choice (TPC) in patients (Pts) with hormone receptor\u2013positive\/HER2\u2212negative (HR+\/HER2\u2212) advanced breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152466_bib0022","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152466_bib0023","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152466_bib0024","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/BD-2009-0281","article-title":"Infiltrating lobular carcinoma of the breast: systemic treatment: infiltrating lobular carcinoma of the breast","volume":"30","author":"Farese","year":"2008","journal-title":"Breast Dis"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152466_bib0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/jpm10040291","article-title":"Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in ER+\/HER2\u2212 patients: a propensity score-matched analysis of a multicenter retrospective patient series","volume":"10","author":"Orlandi","year":"2020","journal-title":"J Pers Med"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152466_bib0026","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41379-022-01084-w","article-title":"Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity","volume":"35","author":"Soong","year":"2022","journal-title":"Mod pathol"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152466_bib0027","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152466_bib0028","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152466_bib0029","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152466_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-020-01324-4","article-title":"Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets","volume":"22","author":"Kurozumi","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"27","key":"10.1016\/j.seminoncol.2026.152466_bib0031","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152466_bib0032","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152466_bib0033","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152466_bib0034","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152466_bib0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s43018-023-00542-x","article-title":"PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial","volume":"4","author":"Voorwerk","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.seminoncol.2026.152466_bib0036","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.breast.2018.11.007","article-title":"Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma","volume":"43","author":"Haque","year":"2019","journal-title":"Breast (Edinburgh)"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152466_bib0037","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152466_bib0038","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152466_bib0039","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152466_bib0040","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152466_bib0041","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152466_bib0042","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neo.2015.01.005","article-title":"Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2","volume":"17","author":"Hortobagyi","year":"2015","journal-title":"Neoplasia (US)"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152466_bib0043","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase ii trial of everolimus in combination with tamoxifen in patients with hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10063","key":"10.1016\/j.seminoncol.2026.152466_bib0044","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet (Br ed)"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152466_bib0045","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.annonc.2022.05.006","article-title":"Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer","volume":"33","author":"Van Baelen","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.seminoncol.2026.152466_bib0046","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMx170012","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152466_bib0047","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152466_bib0048","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152466_bib0049","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152466_bib0050","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"Corrigendum to \u2018first-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis\u2019","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"issue":"12_Supplement","key":"10.1016\/j.seminoncol.2026.152466_sbref0051","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P2-07-24","article-title":"Abstract P2-07-24: results from the phase II study of ROS1 targeting with crizotinib in advanced E-cadherin negative lobular breast cancer (ROLo)","volume":"31","author":"Okines","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152466_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104746","article-title":"192MO Primary endpoint of ROSALINE: a phase II neoadjuvant study of endocrine therapy (ET) and entrectinib in invasive lobular breast carcinoma (ILBC)","volume":"10","author":"Lobo-Martins","year":"2025","journal-title":"ESMO Open"},{"issue":"8_Supplement_2","key":"10.1016\/j.seminoncol.2026.152466_bib0053","doi-asserted-by":"crossref","first-page":"CT235","DOI":"10.1158\/1538-7445.AM2025-CT235","article-title":"Abstract CT235: REPLOT trial: phase II study of repotrectinib with or without fulvestrant in patients with HR+ HER2- metastatic invasive lobular carcinoma previously treated with endocrine therapy and CDK4\/6 inhibition","volume":"85","author":"Mouabbi","year":"2025","journal-title":"Cancer Res (Chicago, Ill)"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152466_bib0054","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1724049","article-title":"Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system","volume":"9","author":"Klarenbeek","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152466_bib0055","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1038\/s41467-019-11716-6","article-title":"Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin","volume":"10","author":"Schipper","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152466_bib0056","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/cancers17030417","article-title":"Unique molecular alteration of lobular breast cancer: association with pathological classification, tumor biology and behavior, and clinical management","volume":"17","author":"Zhang","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152466_bib0057","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s43018-023-00527-w","article-title":"Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment","volume":"4","author":"Onkar","year":"2023","journal-title":"Nat Cancer"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152466_bib0058","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/cancers16223826","article-title":"Mutations matter: unravelling the genetic blueprint of invasive lobular carcinoma for progression insights and treatment strategies","volume":"16","author":"Kontogiannis","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"23","key":"10.1016\/j.seminoncol.2026.152466_bib0059","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/1078-0432.CCR-19-0713","article-title":"BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer","volume":"25","author":"Walsh","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.seminoncol.2026.152466_bib0060","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.212563","article-title":"Re-inforcing the cell death army in the fight against breast cancer","volume":"131","author":"Oudenaarden","year":"2018","journal-title":"J Cell Sci"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152466_bib0061","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00428-005-0003-6","article-title":"Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma","volume":"447","author":"Riva","year":"2005","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152466_bib0062","article-title":"Reporting on invasive lobular breast cancer in clinical trials: a systematic review","volume":"10","author":"Van Baelen","year":"2024","journal-title":"Breast Cancer"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152466_bib0063","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11051350","article-title":"FDG and non-FDG radiopharmaceuticals for PET imaging in invasive lobular breast carcinoma","volume":"11","author":"Gilardi","year":"2023","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152466_bib0064","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2967\/jnumed.115.170456","article-title":"Initial results of a prospective clinical trial of 18F-fluciclovine PET\/CT in newly diagnosed invasive ductal and invasive lobular breast cancers","volume":"57","author":"Ulaner","year":"2016","journal-title":"J Nucl Med (1978)"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152466_bib0065","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1101\/gr.111534.110","article-title":"Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers","volume":"21","author":"S\u00e9randour","year":"2011","journal-title":"Genome Res"},{"issue":"57","key":"10.1016\/j.seminoncol.2026.152466_bib0066","doi-asserted-by":"crossref","first-page":"96496","DOI":"10.18632\/oncotarget.20410","article-title":"Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy","volume":"8","author":"Lyons","year":"2017","journal-title":"Oncotarget"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:41:06Z","timestamp":1774946466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426000102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0093775426000102"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152466","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the management of metastatic lobular breast cancer: Current evidence and emerging treatments","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152466"}}